In January, it was approved as the Guangdong Provincial Biosynthetic Engineering Technology Research Center.
In March, the Guangzhou strain development center started operation.
In April, it was approved for domestic medical PHA material registration.
In December, it completed the A+ round of financing.
In December, it was rated as a specialized and new small and medium-sized enterprise in Guangdong Province.